Capricor Therapeutics has executed a collaboration agreement and exclusive license option with Janssen Biotech. It was reported that the contract has been signed for the development of new cardiovascular products. According to the contract, both firms will collaborate on the development of Capricor's cell therapy programme for cardiovascular applications, including its lead product, CAP-1002.

After the contract, both firms will collaborate on elements of cell manufacturing development, while Capricor will contribute to the costs of the manufacturing collaboration and receive an upfront payment of USD 12.5 million from Janssen. According to the contract, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until 60 days after delivery by Capricor of the six-month follow-up results from Phase II of Capricor's ALLSTAR clinical trial for CAP-1002.